Tianjing Bio will announce Uliledlimab's Phase 1 clinical research results at the 2021 ASCO annual meeting

Tianjing Biotech announced today that during the 2021 American Society of Clinical Oncology (ASCO) annual meeting to be held from June 4 to 8, 2021, it will announce its self-developed CD73 antibody uliledlimab (also known as TJD5) and A U.
S.
Phase 1 clinical study data of tilizumab (Taishengqi®) in the treatment of patients with advanced cancer
.

The clinical research results have been selected by the American Society of Clinical Oncology (ASCO) as the 2021 annual conference poster and successfully selected as the "Top 12" research abstract of this year.

Uliledlimab is a highly differentiated CD73 humanized antibody that effectively relieves the immune suppression of the tumor microenvironment by inhibiting the production of adenosine, and improves the immune response of anti-tumor immune cells
.

Preclinical studies have shown that the combination of uliledlimab and PD-(L)1 antibody can produce a better anti-tumor synergistic effect than PD-(L)1 antibody monotherapy

The US Phase 1 dose-climbing trial data showed that the combination therapy of uliledlimab and atelizumab has good safety and tolerability, no dose-limiting toxicity (DLT) events occurred, and treatment-related adverse events were all Mild grade 1 or 2
.

In addition, at medium/high dose levels (>=10mg/kg), the pharmacokinetic (PK) characteristics of uliledlimab are linear, and the soluble CD73 on the peripheral blood or on the cell surface has reached full receptor occupancy, and there is no " Hook effect"

The report details are as follows:

Abstract number	2511
title	Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer
Report session	Developmental Therapeutics-Immunotherapy
report time	June 4, 2021, 9 a. m. (Eastern Time)
Reporter	Professor Francisco Robert, University of Alabama at Birmingham School of Medicine

 

Dr.
Shen Huaqiong, CEO of Tianjing Bio, said: “Currently, the non-response rate of existing PD-1/PD-L1 inhibitor monotherapy in certain tumor types is still very high.
We look forward to relying on the unique mechanism of action of uliledlimab.
Solve the problem of drug resistance of immune checkpoint inhibitors through combination medication
.

The data of this phase 1 clinical trial fully demonstrates the potential of uliledlimab to treat a variety of cancers, especially for patients who do not respond to PD-1/PD-L1 inhibitors

At the same time, uliledlimab has made many progress in clinical development in China
.

Currently, Tianjing Biologics is simultaneously developing a single drug of uliledlimab and its combination with tereprizumab (Tuoyi®) in China to treat advanced or metastatic cancers (including those that do not respond to or are intolerant to existing treatments).
Non-small cell lung cancer) clinical research in patients